Drug Name | Mechanism of Action | Target | Score |
---|---|---|---|
Tipifarnib | Farnesyltransferase inhibitor | FNTA, FNTB | -96.1 |
Tofacitinib | JAK inhibitor | JAK3, JAK1, JAK2, CYP2C19, TYK2 | -95.81 |
GSK-1070916 | Aurora kinase inhibitor | AURKB, AURKC, AURKA, CYP2D6, CYP3A4 | -94.93 |
Mestranol | Estrogen receptor agonist | ESR1 | -94.48 |
Ruxolitinib | JAK inhibitor | JAK1, JAK2, TYK2, JAK3 | -93.19 |
XMD-1150 | Leucine rich repeat kinase inhibitor | LRRK2 | -92.64 |
TPCA-1 | IKK inhibitor | IKBKB | -91.9 |
PPT | Estrogen receptor agonist | ESR1 | -91.84 |
7,4'-dihydroxyflavone | Opioid receptor antagonist | CYP19A1 | -91.29 |
Phorbol-12-myristate-13-acetate | PKC activator | CD4, KCNT2, PRKCA, TRPV4 | 90.49 |
BX-795 | IKK inhibitor | PDPK1, CDK2, CHEK1, GSK3B, IKBKE, KDR, PDK1, TBK1 | 92.53 |
Arecaidine | Acetylcholine receptor agonist | CHRM1, CHRM2, CHRM3, CHRM4 | 92.67 |
NSC-94258 | Antineoplastic | AKR1B1, CYP19A1, HSD17B1 | 93.08 |
Scoulerine | Adrenergic receptor antagonist, GABA receptor antagonist, Serotonin receptor antagonist | ADRA1D, ADRA2A, GABRA1 | 95.29 |
Prostratin | PKC activator | PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ | 95.81 |
Ingenol | PKC activator | PRKCD, PRKCE | 96.05 |